Lu 29-252

Lu 29-252 is a selective sigma σ2 receptor ligand which was under development for the treatment of anxiety disorders but was never marketed. It reached the preclinical stage of development prior to the discontinuation of its development. The drug was under development by Lundbeck.
Wikipedia contributors, "Lu 29-252", Wikipedia, revision 1372022373, retrieved 20 November 2026, source, CC BY-SA 4.0.